MA31763B1 - Inhibiteurs de kinase de type polo - Google Patents

Inhibiteurs de kinase de type polo

Info

Publication number
MA31763B1
MA31763B1 MA32753A MA32753A MA31763B1 MA 31763 B1 MA31763 B1 MA 31763B1 MA 32753 A MA32753 A MA 32753A MA 32753 A MA32753 A MA 32753A MA 31763 B1 MA31763 B1 MA 31763B1
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
compounds
inhibitors type
polo
type polo
Prior art date
Application number
MA32753A
Other languages
Arabic (ar)
English (en)
Inventor
Sheldon X Cao
Victoria Feher
Takashi Ichikawa
Benjamin Jones
Stephen W Kaldor
Andre A Kiryanov
Yan Liu
Christopher Mcbride
Srinivasa Reddy Natala
Zhe Nie
Jeffrey A Stafford
Betty Lam
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40219644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31763(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA31763B1 publication Critical patent/MA31763B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La présente invention concerne des composés répondant à la formule suivante, lesquels sont destinés à être utilisés avec des kinases : (i), les variables étant telles que définies dans le présent document. L'invention concerne également des compositions pharmaceutiques, des trousses et des articles de fabrication contenant de tels composés, des procédés et des intermédiaires utiles pour la fabrication des composés, et des procédés d'utilisation desdits composés
MA32753A 2007-09-25 2010-04-08 Inhibiteurs de kinase de type polo MA31763B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97512707P 2007-09-25 2007-09-25
US3730308P 2008-03-17 2008-03-17
PCT/US2008/077558 WO2009042711A1 (fr) 2007-09-25 2008-09-24 Inhibiteurs de kinase de type polo

Publications (1)

Publication Number Publication Date
MA31763B1 true MA31763B1 (fr) 2010-10-01

Family

ID=40219644

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32753A MA31763B1 (fr) 2007-09-25 2010-04-08 Inhibiteurs de kinase de type polo

Country Status (26)

Country Link
US (4) US20110201818A1 (fr)
EP (3) EP2564850B1 (fr)
JP (2) JP5372939B2 (fr)
KR (2) KR20140097440A (fr)
CN (2) CN101917995A (fr)
AR (1) AR071729A1 (fr)
AU (1) AU2008304417B2 (fr)
BR (1) BRPI0817315A2 (fr)
CA (2) CA2699607A1 (fr)
CL (1) CL2008002852A1 (fr)
CO (1) CO6270231A2 (fr)
CR (1) CR11370A (fr)
DO (1) DOP2010000091A (fr)
EA (1) EA019487B1 (fr)
EC (1) ECSP10010129A (fr)
ES (1) ES2488966T3 (fr)
GE (1) GEP20125704B (fr)
MA (1) MA31763B1 (fr)
MX (2) MX2010003249A (fr)
MY (1) MY152283A (fr)
NZ (1) NZ584760A (fr)
PE (1) PE20090710A1 (fr)
TN (1) TN2010000131A1 (fr)
TW (1) TWI436769B (fr)
WO (2) WO2009042711A1 (fr)
ZA (1) ZA201002543B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479434T1 (de) 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
BRPI0817315A2 (pt) * 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
CN101878216B (zh) * 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
WO2009153197A1 (fr) 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Pyrimidodiazépines à substitution halogéno en tant qu’inhibiteurs de plkl
US8049005B2 (en) 2009-03-31 2011-11-01 Arqule, Inc. Substituted tetrahydropyrazolo-pyrido-azepine compounds
WO2010115279A1 (fr) 2009-04-06 2010-10-14 University Health Network Inhibiteurs de kinases et procédé de traitement du cancer avec ceux-ci
MX2012003484A (es) 2009-09-25 2012-04-20 Vertex Pharma Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
SG179207A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
CN102762568A (zh) 2009-12-23 2012-10-31 伊兰药品公司 作为polo样激酶的抑制剂的蝶啶酮
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
WO2012061342A2 (fr) 2010-11-01 2012-05-10 Arqule, Inc. Composés de benzo-imidazo-pyrido-diazépine substitués
US9006477B2 (en) * 2011-07-07 2015-04-14 Ihara Chemical Industry Co., Ltd. Method for producing nitrobenzene compound
WO2013058344A1 (fr) * 2011-10-21 2013-04-25 武田薬品工業株式会社 Procédé de prédiction de l'effet d'un inhibiteur de plk1
TR201902875T4 (tr) * 2013-10-18 2019-03-21 Univ Health Network Plk-4 inhibitörünün tuz ve kristal formları.
EP3099693A4 (fr) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Utilisations des dérivés de diazépane
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
CA2986441A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Therapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
TWI920577B (zh) * 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
EP3959209A4 (fr) 2019-04-24 2022-12-28 University Health Network Forme cristalline s4 d'un inhibiteur de plk4 (1r,2s)-(e)-2-(3-(4-((cis-2,6-diméthylmorpholino)méthyl)styryl)- 1 h-imidazol-6- yl)-5'-méthoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (fr) * 2020-12-31 2022-07-07 (주) 업테라 Dérivé de pyrimidodiazépine servant d'inhibiteur sélectif de plk1
US12577253B2 (en) 2021-02-08 2026-03-17 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. 5,6-dihydrothieno[3,4-h]quinazoline compound
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (fr) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026112260A1 (fr) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026122764A2 (fr) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026128688A2 (fr) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026161839A1 (fr) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
JP2003509425A (ja) 1999-09-15 2003-03-11 ワーナー−ランバート・カンパニー キナーゼ阻害剤としてのプテリジノン
HK1053831A1 (zh) 1999-09-17 2003-11-07 Basf Aktiengesellschaft 作为治疗药物的激酶抑制剂
UY27427A1 (es) 2001-09-04 2003-03-31 Boehringer Ingelheim Pharma Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (fr) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
EP1632493A1 (fr) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dérivés de dihydropteridine, méthodes de préparation et utilisation en tant que médicament
WO2006021548A1 (fr) 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinones, leur procede de production, et leur utilisation en tant que medicaments
ATE479434T1 (de) 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
CN101448830A (zh) 2006-05-19 2009-06-03 阿斯利康(瑞典)有限公司 作为抗增殖剂的二氢碟啶化合物
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
CN101636399B (zh) * 2007-03-22 2012-04-18 武田药品工业株式会社 可用作plk1抑制剂的取代的嘧啶并二氮杂*
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
BRPI0817315A2 (pt) * 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
WO2009153197A1 (fr) 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Pyrimidodiazépines à substitution halogéno en tant qu’inhibiteurs de plkl

Also Published As

Publication number Publication date
EA201070395A1 (ru) 2010-10-29
US20090281092A1 (en) 2009-11-12
US20110082111A1 (en) 2011-04-07
HK1145144A1 (en) 2011-04-08
ZA201002543B (en) 2011-11-30
CO6270231A2 (es) 2011-04-20
US8318727B2 (en) 2012-11-27
EP2197442B1 (fr) 2012-09-12
MY152283A (en) 2014-09-15
KR101444924B1 (ko) 2014-10-07
WO2009042711A4 (fr) 2009-06-04
CL2008002852A1 (es) 2009-03-27
JP2010540464A (ja) 2010-12-24
JP5372939B2 (ja) 2013-12-18
JP2010540463A (ja) 2010-12-24
KR20140097440A (ko) 2014-08-06
TWI436769B (zh) 2014-05-11
ECSP10010129A (es) 2010-06-29
CN103122001A (zh) 2013-05-29
TW200927135A (en) 2009-07-01
MX2010003244A (es) 2010-04-21
EA019487B1 (ru) 2014-04-30
CN101917995A (zh) 2010-12-15
CA2700295A1 (fr) 2009-04-02
WO2009042806A1 (fr) 2009-04-02
TN2010000131A1 (en) 2011-09-26
NZ584760A (en) 2012-03-30
AU2008304417A1 (en) 2009-04-02
GEP20125704B (en) 2012-12-10
EP2564850B1 (fr) 2014-08-13
US20100222575A1 (en) 2010-09-02
MX2010003249A (es) 2010-11-09
DOP2010000091A (es) 2010-07-31
WO2009042711A1 (fr) 2009-04-02
PE20090710A1 (es) 2009-07-15
EP2205241B1 (fr) 2014-05-21
KR20100087292A (ko) 2010-08-04
US20110201818A1 (en) 2011-08-18
BRPI0817315A2 (pt) 2015-03-17
CA2699607A1 (fr) 2009-04-02
EP2197442A1 (fr) 2010-06-23
EP2205241A1 (fr) 2010-07-14
US8026234B2 (en) 2011-09-27
US8202990B2 (en) 2012-06-19
CR11370A (es) 2010-07-16
AR071729A1 (es) 2010-07-14
AU2008304417B2 (en) 2013-07-18
EP2564850A1 (fr) 2013-03-06
ES2488966T3 (es) 2014-09-01

Similar Documents

Publication Publication Date Title
MA32615B1 (fr) Inhibiteurs de cmet
MA31151B1 (fr) Inhibiteurs de mapk/erk kinase
MA32391B1 (fr) Activateurs de la glucokinase
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA30057B1 (fr) Nucleosides antiviraux
MA31586B1 (fr) Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA30655B1 (fr) Composes organiques.
MA29629B1 (fr) Inhibiteurs de l'histone deacetylase
TNSN08359A1 (fr) Derives d'amines
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA31580B1 (fr) Derives de bicyclolactames substitués
ATE479687T1 (de) Kinaseinhibitoren
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
MA29393B1 (fr) Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase
MA30781B1 (fr) Inhibiteur de kinase
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
TW200745045A (en) Imidazole based LXR modulators
NO20071476L (no) Antidiuretiske midler.
TNSN08306A1 (fr) Imidazoles substitutes et leur utilisation comme pesticides